Literature DB >> 24102009

Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).

Bojan Zaric1, Vladimir Stojsic, Aleksandar Tepavac, Tatjana Sarcev, Paul Zarogoulidis, Kaid Darwiche, Kosmas Tsakiridis, Ilias Karapantzos, Georgios Kesisis, Ioanna Kougioumtzi, Nikolaos Katsikogiannis, Nikolaos Machairiotis, Aikaterini Stylianaki, Christophoros N Foroulis, Konstantinos Zarogoulidis, Branislav Perin.   

Abstract

Lung cancer is one of the most common human malignancies and remains the leading cause of cancer related deaths worldwide. Many recent technological advances led to improved diagnostics and staging of lung cancer. With development of new treatment options such as targeted therapies there might be improvement in progression free survival of patients with advanced stage non-small cell lung cancer (NSCLC). Improvement in overall survival is still reserved for selected patients and selected treatments. One of the mostly investigated therapeutic options is adjuvant treatment. There are many open issues in selection of patients and administration of appropriate adjuvant treatment.

Entities:  

Keywords:  Adjuvant therapy; chemotherapy; non-small cell lung cancer (NSCLC); radiotherapy

Year:  2013        PMID： 24102009      PMCID： PMC3791489          DOI： 10.3978/j.issn.2072-1439.2013.05.16

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  42 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.

Authors:  J A Zuccato; P M Ellis
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

3.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques.

Authors:  B Dautzenberg; R Arriagada; A B Chammard; A Jarema; M Mezzetti; K Mattson; J L Lagrange; C Le Pechoux; B Lebeau; C Chastang
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.

Authors:  Steven J Feigenberg; Alexandra L Hanlon; Corey Langer; Melvyn Goldberg; Nicos Nicolaou; Michael Millenson; Lawrence R Coia; Rachelle Lanciano; Benjamin Movsas
Journal:  J Thorac Oncol       Date:  2007-04       Impact factor: 15.609

5.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

Review 6.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

7.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

Authors:  Ming-Sound Tsao; Sarit Aviel-Ronen; Keyue Ding; Davina Lau; Ni Liu; Akira Sakurada; Marlo Whitehead; Chang-Qi Zhu; Robert Livingston; David H Johnson; James Rigas; Lesley Seymour; Timothy Winton; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

8.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

Authors:  D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 10.  The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Authors:  Masahiro Tsuboi; Tatsuo Ohira; Hisashi Saji; Kuniharu Miyajima; Naohiro Kajiwara; Osamu Uchida; Jitsuo Usuda; Harubumi Kato
Journal:  Ann Thorac Cardiovasc Surg       Date:  2007-04       Impact factor: 1.520
View more
  17 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.

Authors:  Dongfang Tang; Hongliang Liu; Yuchen Zhao; Danwen Qian; Sheng Luo; Edward F Patz; Li Su; Sipeng Shen; David C ChristianI; Wen Gao; Qingyi Wei
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 6.166

3.  SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer.

Authors:  Nianli Liu; Aoxing Chen; Ning Feng; Xiaochen Liu; Longzhen Zhang
Journal:  Med Oncol       Date:  2021-04-09       Impact factor: 3.064

4.  Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells.

Authors:  Kuizhong Shan; Yujiang Deng; Zhiquan Du; Peiyu Yue; Sufang Yang
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

5.  Treatment of a recurrent pulmonary artery leiomyosarcoma with a combination of surgery, chemotherapy, and radiotherapy: A case report and literature review.

Authors:  Yin Lv; Fan Wang; Wenchuan Qian; Guoping Sun
Journal:  Oncol Lett       Date:  2015-02-11       Impact factor: 2.967

6.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147

7.  A multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience.

Authors:  Theodora Tsiouda; Paul Zarogoulidis; Dimitris Petridis; Nikolaos Pezirkianidis; Ioannis Kioumis; Lonny Yarmus; Haidong Huang; Qiang Li; Wolfgang Hohenforst-Schmidt; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Georgia Pitsiou; Theodoros Kontakiotis; Paraskevi Argyropoulou; George Kyriazis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-05-10       Impact factor: 4.207

8.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

9.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

Review 10.  EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?

Authors:  Aleksandar Milovancev; Vladimir Stojsic; Bojan Zaric; Tomi Kovacevic; Tatjana Sarcev; Branislav Perin; Konstantinos Zarogoulidis; Katerina Tsirgogianni; Lutz Freitag; Kaid Darwiche; Drosos Tsavlis; Athanasios Zissimopoulos; Grigoris Stratakos; Paul Zarogoulidis
Journal:  Onco Targets Ther       Date:  2015-10-13       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.